Resource utility {#S1}
================

Mutations in *ABCA4* gene can cause a wide range of recessive retinal disorders, including recessive Stargardt disease (STGD1), the most common form of inherited juvenile macular degeneration ([@R1]; [@R3]). Several novel pharmacologic, gene, and stem-cell therapies are being developed as therapeutic strategies to protect or improve vision for patients with STGD1 ([@R2]). The generation of iPSC lines from patients carrying mutations in *ABCA4* will be valuable *in vitro* models for the screening of new treatments.

Resource details {#S2}
================

Two patients were diagnosed with recessive Stargardt disease at Institut de Microcirurgia Ocular (IMO). Analysis of the *ABCA4* gene identified one splicing mutation and one missense variant in the first patient (STGD_1), and three missense variants (in *cis* position) and one frameshift mutation in the second (STGD_2) ([@R4]). Detailed clinical and genetic data is shown in [Table 1](#T1){ref-type="table"}. Dermal fibroblasts were obtained from a skin biopsy and reprogrammed into iPSC using non-integrative Sendai virus containing the reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC. Approximately three weeks after transduction, iPSC colonies were manually picked and expanded. One iPSC colony for each patient was fully characterized at the genetic and molecular level (STGD1_FiPS4F1.5 and STGD2_FiPS4F1.7). The results of these analyses are summarized in [Table 2](#T2){ref-type="table"}. The resulting iPSC lines showed typical human embryonic stem cell morphology, with large and well-defined polygonal colonies, high nuclear/cytoplasmic ratio and prominent nucleoli ([Fig. 1A](#F1){ref-type="fig"}). Both iPSC lines had normal karyotype, 46XX and 46XY respectively ([Fig. 1B](#F1){ref-type="fig"}), did not express Sendai virus and reprogramming genes and were *Mycoplasma* negative ([Supplementary file](#SD1){ref-type="supplementary-material"}). For the DNA fingerprinting analysis, we used 16 different markers, which confirmed that each iPSC line had the same genetic background as the donor fibroblasts ([Table 2](#T2){ref-type="table"}). Immunocytochemistry and flow cytometry assays showed that the iPSC lines were positive for the pluripotency transcription factors OCT4, NANOG and SOX2, and the surface marker SSEA4 ([Fig. 1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}). To verify the ability of these iPSC lines to differentiate into the three germ layers, an *in vitro* functional differentiation test was performed, confirming that both iPSC lines could generate endoderm, mesoderm and ectoderm ([Fig. 1E](#F1){ref-type="fig"}). Finally, the presence of the *ABCA4* mutations in the iPSC lines was verified by Sanger sequencing (c.4253 + 4C \> T and c.6089G \> A variants in STGD1_FiPS4F1.5 cells, and c.514G \> A, c.2023G \> A, c.6148G \> C and c.3211_3212insGT mutations in STGD2_FiPS4F1.7 cells) ([Fig. 1F](#F1){ref-type="fig"}).

Materials and methods {#S3}
=====================

Reprogramming of skin fibroblasts {#S4}
---------------------------------

Fibroblasts were expanded in DMEM (cat\# 11960077, Life Technologies) supplemented with 10% FBS (cat\# 10082147, Life Technologies) and 1× penicillin-streptomycin (cat\# 15140122, Life Technologies), and reprogrammed following the manufacturer instructions (CytoTune™-iPS 2.0 Sendai Reprogramming Kit, cat\# A16518, ThermoFisher Scientific). Six days after transduction, 2 × 10^4^ cells were seeded on irradiated mouse embryonic fibroblasts (MEFs) (cat\# A34181, ThermoFisher Scientific) in six wells of a 6-well plate, and DMEM media was replaced with hES media, containing DMEM/Ham's F-12 (cat\# 11320--033, Life Technologies) supplemented with 20% KSR (cat \# 10828028 Life Technologies), 1× non-essential amino acids (cat\# 11140076, Life Technologies), 1× penicillin-streptomycin, 1× glutamine (cat\# 25030081, Life Technologies), 1× β-mercaptoethanol (cat\# 21985023, Life Technologies), and 10 ng/ml of FGF2 (cat\# 233-FB, R&D Systems). Three weeks after reprogramming, 20 colonies were manually picked and placed onto a MEFs-coated 24-well plate. Selected iPSC colonies were expanded on MEFs for six passages, then cells were cultured and adapted to feeder-free conditions, onto Matrigel-coated plates (cat\# CB 40230, Corning) in mTeSR1 medium (cat\# 5850, StemCell Technologies). Cells were weekly subcultured 1:10 using 50 mM EDTA in phosphate buffered saline (PBS) without calcium and magnesium and incubated at 37 °C in 5% CO~2~ atmosphere.

Karyotype analysis {#S5}
------------------

After six passages, karyotype was performed on twenty G-banded metaphase cells at 450--500 band resolution (Cell Line Genetics).

Mutation analysis {#S6}
-----------------

Genomic DNA was isolated from 10^6^ cells using the DNeasy Blood & Tissue Kit (cat\# 69504, Qiagen) following manufacturer's instructions. PCR amplification was performed using DNA AmpliTools Green Master Mix (cat\# 4749, Biotools) and specific primers flanking the *ABCA4* mutations ([Table 3](#T3){ref-type="table"}) in a final volume of 50 μl. The PCR was performed using a SimpliAmp™ Thermal Cycler (Applied Biosystems) in a three-step process: denaturation for 2 min at 95 °C, followed by 35 cycles of 20 s at 94 °C, 30 s at 55 °C, and 30 s at 72 °C. The resulting PCR products were Sanger sequenced (Macrogen).

STR analysis {#S7}
------------

Identity analysis was performed by Cell Line Genetics on the fibroblast cells and the established iPSC line using the PowerPlex 16 System (cat\# DC6531, Promega).

In vitro differentiation assay {#S8}
------------------------------

*In vitro* functional differentiation was performed using the Human Pluripotent Stem Cell Functional Identification kit (cat\# SC022, R&D Systems). Cells were fixed and stained to detect endoderm, mesoderm and ectoderm specific markers (SOX17, Brachyury and OTX2, respectively) ([Table 3](#T3){ref-type="table"}).

Immunocytochemistry {#S9}
-------------------

Cells were fixed in 4% paraformaldehyde (PFA) for 15 min at room temperature (RT) and washed twice with 1× PBS before being permeabilized with 0.2% Triton X-100 in 1× PBS for 10 min. Cells were rinsed twice in 1% bovine serum albumin (BSA) in 1× PBS and blocked for 30 min at RT with DAKO blocking buffer (Agilent). Cells were incubated with primary antibodies in 1% BSA at 4 °C for O/N, and then washed twice and incubated with the appropriate secondary antibody for 1 h at RT ([Table 3](#T3){ref-type="table"}). Finally, cell nuclei were stained with DAPI (1:1000) at RT for 5 min, washed twice and visualized and captured using an Olympus IX73 inverted microscope connected to a XM10 monochrome camera (Olympus, Tokyo, Japan).

Flow cytometry {#S10}
--------------

Single cell suspension was obtained using EDTA and cells were fixed in 4% PFA for 15 min. For nuclear staining, cells were also permeabilized with cold methanol for 20 min on ice. Cells were incubated for 15 min at RT with conjugated antibodies and isotype negative controls diluted with DMEM supplemented with 10% FBS ([Table 3](#T3){ref-type="table"}), then FACS analyzed (Bio-Rad S3e (Bio-Rad)). FACS data were analyzed using FlowJo software.

RNA isolation and RT-PCR analysis {#S11}
---------------------------------

The clearance of Sendai virus and reprogramming factors was confirmed by RT-PCR after nine passages. Briefly, total RNA from 1 × 10^6^ cells was obtained by using the RNeasy Protect Cell Mini Kit (cat\# 74624, Qiagen), according to manufacturer's instructions. Then, cDNA was generated by reverse transcription using Transcriptor High Fidelity cDNA Synthesis Kit (cat\# 05091284001, Roche Diagnostics). *GAPDH* was used as control for normalization. The PCR was performed in a SimpliAmp™ Thermal Cycler (Applied Biosystems) using the DNA AmpliTools Green Master Mix (cat\# 4749, Biotools) in a final volume of 25 μl (primer sequences are given in [Table 3](#T3){ref-type="table"}). For amplification of *GAPDH*, a two-step PCR was performed as follows: first denaturation for 2 min at 95 °C, followed by 32 cycles of 20 s at 95 °C and 2 min at 63 °C. For amplification of Sendai virus genome and reprogramming factors, we performed a three-step PCR: denaturation for 2 min at 95 °C, followed by 40 cycles of 30 s at 95 °C, 30 s at 55 °C, and 30 s at 72 °C. The cDNA from cells collected one week after the virus infection was used as a positive control for the expression of Sendai virus genome and reprogramming factors.

Mycoplasma detection {#S12}
--------------------

The presence of mycoplasma was regularly tested by using e-Myco™ plus Mycoplasma PCR Detection Kit (cat\# 25234, Intron).

Supplementary Material {#SM1}
======================

We are grateful to the patients for the participation in this study. The project leading to these results has received funding from "la Caixa" Banking Foundation under the project code LCF/PR/PR17/11120006, and the Fundació de Recerca de l'Institut de Microcirurgia Ocular.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2019.101389>.

![Characterization of the iPSC lines.](nihms-1040295-f0001){#F1}

###### 

Summary of lines.

  iPSC line names                                                                                Abbreviation in figures   Gender   Age   Ethnicity   Genotype of locus                          Disease
  ---------------------------------------------------------------------------------------------- ------------------------- -------- ----- ----------- ------------------------------------------ -------------------
  STGD1_FiPS4F1.5                                                                                STGD_1                    Female   29    Caucasian   *ABCA4* compound heterozygous mutations    Stargardt disease
  Allele 1: c.4253 + 4C \> T                                                                                                                                                                     
  Allele 2: c.6089G \> A (p.Arg2030Gln)                                                                                                                                                          
  STGD2_FiPS4F1.7                                                                                STGD_2                    Male     20    Caucasian   *ABCA4* compound heterozygous mutations:   Stargardt disease
  Allele 1: c.514G \> A (p.Gly172Ser); c.2023G \> A (p.Val675Ile); c.6148G \> C (p.Val2050Leu)                                                                                                   
  Allele 2: c.3211_3212insGT (p.Ser1071fs\*14)                                                                                                                                                   

###### 

Characterization and validation.

  Classification                                                    Test                                                         Result                                                                                                             Data
  ----------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------
  Morphology Phenotype                                              Photography                                                  Normal                                                                                                             [Fig. 1](#F1){ref-type="fig"} panel A
  Qualitative analysis Immunocytochemistry                          Assess staining of pluripotency markers: OCT4, SOX2, NANOG   [Fig. 1](#F1){ref-type="fig"} panel C                                                                              
  Quantitative analysis Flow cytometry                              STGD_1: SSEA, 99.5%; NANOG, 92.5%; OCT4, 86.8%               [Fig. 1](#F1){ref-type="fig"} panel D                                                                              
  STGD_2: SSEA, 99.4%; NANOG, 92.8%; OCT4, 90.5%                                                                                                                                                                                                    
  Genotype                                                          Karyotype (G-banding) and resolution                         STGD_1: 46, XX                                                                                                     [Fig. 1](#F1){ref-type="fig"} panel B
  STGD_2: 46, XY                                                                                                                                                                                                                                    
  Resolution 450--500                                                                                                                                                                                                                               
  Identity                                                          STR analysis                                                 16 *loci* analyzed, all matching                                                                                   Available with the authors
  Mutation analysis (IF APPLICABLE)                                 Sequencing                                                   STGD_1: compound heterozygous, splicing and missense mutations                                                     [Fig. 1](#F1){ref-type="fig"} panel F
  STGD_2: compound heterozygous, missense and insertion mutations                                                                                                                                                                                   
  Microbiology and virology                                         Mycoplasma                                                   Mycoplasma testing by PCR. Negative                                                                                [Supplementary file](#SD1){ref-type="supplementary-material"}
  Differentiation potential                                         Directed differentiation                                     Positive OTX2 ectodermal staining, positive Brachyury mesodermal staining and positive SOX17 endodermal staining   [Fig. 1](#F1){ref-type="fig"} panel E
  Donor screening (OPTIONAL)                                        N/A                                                          N/A                                                                                                                N/A
  Genotype additional info (OPTIONAL)                               N/A                                                          N/A                                                                                                                N/A

###### 

Reagents details.

  Antibodies used for immunocytochemistry/flow-citometry                                                            
  -------------------------------------------------------- ----------------------------------------------- -------- --------------------------------------------------------------------------------------------------------------
  Pluripotency Marker                                      Rabbit anti-OCT4 (Alexa Fluor 488 Conjugate)    1:50     Cell Signaling Technology Cat\# 5177S, RRID: [AB_10693303](http://antibodyregistry.org/AB_10693303)
  Pluripotency Marker                                      Mouse anti-SOX2 (Alexa Fluor 488 Conjugate)     1:50     Santa Cruz Biotechnology Cat\# sc-365823 AF488, RRID: [AB_10842165](http://antibodyregistry.org/AB_10842165)
  Pluripotency Marker                                      Rabbit anti-NANOG                               1:400    Cell Signaling Technology Cat\# 4903P, RRID: [AB_10559205](http://antibodyregistry.org/AB_10559205)
  Pluripotency Marker                                      Mouse anti-SSEA-4 (Alexa Fluor 488 Conjugate)   1:20     BD Pharmingen Cat\#560308, RRID: [AB_1645371](http://antibodyregistry.org/AB_1645371)
  Pluripotency Marker                                      Mouse anti-NANOG (Alexa Fluor 488 Conjugate)    1:10     BD Pharmingen Cat\#560791, RRID: [AB_1937305](http://antibodyregistry.org/AB_1937305)
  Differentiation Marker                                   Goat anti-OTX2                                  1:20     R&D Systems Cat\# AF1979, RRID: [AB 2157172](http://antibodyregistry.org/AB_2157172)
  Differentiation Marker                                   Goat anti-Brachyury                             1:20     R&D Systems Cat\# AF2085, RRID: [AB_2200235](http://antibodyregistry.org/AB_2200235)
  Differentiation Marker                                   Goat anti-SOX17 (NL557 Conjugate)               1:10     R&D Systems Cat\# NL1924R, RRID: [AB_2195645](http://antibodyregistry.org/AB_2195645)
  Secondary antibody                                       Rabbit anti-Goat IgG Alexa Fluor 488            1:1000   Thermo Fisher Scientific Cat\# A27012, RRID: [AB_2536077](http://antibodyregistry.org/AB_2536077)
  Secondary antibody                                       Goat anti-Rabbit IgG Alexa Fluor 488            1:1000   Thermo Fisher Scientific Cat\# A11008, RRID: [AB_143165](http://antibodyregistry.org/AB_143165)

  Primers                                                       
  ------------------------ ------------------------------------ -------------------------------
  Sendai virus detection   *SeV,* 181 bp                        GGATCACTAGGTGATATCGAGC
                                                                ACCAGACAAGAGTTTAAGAGATATGTATC
  Transgene detection      *KOS,* 528 bp                        ATGCACCGCTACGACGTGAGCGC
                                                                ACCTTGACAATCCTGATGTGG
  Transgene detection      *KLF4,* 410 bp                       TTCCTGCATGCCAGAGGAGCCC
                                                                AATGTATCGAAGGTGCTCAA
  Transgene detection      *c-MYC,* 532 bp                      TAACTGACTAGCAGGCTTGTCG
                                                                TCCACATACAGTCCTGGATGATGATG
  House-keeping gene       *GAPDH,* 983 bp                      TGAAGGTCGGAGTCAACGGATTTGG
                                                                CATGTAGGCCATGAGGTCCACCAC
  Mutation sequencing      *ABCA4* (c.514G \> A), 423 bp        GGCAAGAGCCTCACCTCTAG
                                                                TAAATACAAGGCATTAAGTGATGG
  Mutation sequencing      *ABCA4* (c.2023G \> A), 511 bp       AGCCCATTAAATGTCCAGGGGAGG
                                                                GTTGGCTAAAAGGAAGGGCTG
  Mutation sequencing      *ABCA4* (c.3211_3212insGT), 409 bp   TAAACATCTAAGAGGCAGCACC
                                                                TCACCAAGTCACTGATAAACCC
  Mutation sequencing      *ABCA4* (c.4253 + 4C \> T), 473 bp   AGAAGCCCAACCCTCTCCAC
                                                                CTTCCCAAGCAGTCCTGCCT
  Mutation sequencing      *ABCA4* (c.6089G \> A), 415 bp       ATGCATTTCTGAAGCCAAATAGG
                                                                AGACACATAGTAAACATTTGTTGG
  Mutation sequencing      *ABCA4* (c.6148G \> C), 435 bp       GCCTGTTTCAGCCTAGCTGG
                                                                GCTGTGTGAACCAAACACTGG
